Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System
March 11, 2024 08:00 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces peer-reviewed publication showing correlation of software lesion size to histopathology, only FDA-cleared laser with correlation
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
March 01, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation...
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock
February 29, 2024 08:00 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to...
ClearPoint Neuro Launches Proposed Public Offering of Common Stock
February 28, 2024 16:45 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to...
ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model
February 21, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces FDA Clearance and first-in-human cases using 2.2 Software with integrated Maestro Brain Modeling, and publication in NeuroImage
ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo
January 24, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
First successful procedure with ClearPoint Prism Neuro Laser Therapy System and Neuro Navigation System by Kaleida Health in Buffalo.
ClearPoint Neuro gibt erste erfolgreiche EU-MDR-Zertifizierung und Genehmigung zur Lieferung von Produkten nach Europa bekannt
January 22, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Kalifornien, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (das „Unternehmen“), ein weltweit tätiges Unternehmen im Bereich Medizinprodukte sowie Zell- und...
ClearPoint Neuro annonce être arrivé pour la première fois au terme du processus de certification de conformité au Règlement européen MDR et obtenu l’autorisation d’expédier son produit en Europe
January 22, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Californie, 22 janv. 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq : CLPT (la « Société »), une entreprise internationale spécialisée dans les dispositifs médicaux, les...
ClearPoint Neuro annoncerer første EU MDR certificeringssucces og godkendelse til at sende produkt til Europa
January 22, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Californien, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) ("Virksomheden"), en global enhed, celle- og genterapi-virksomhed, der tilbyder præcis navigation...
ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe
January 22, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces first EU MDR certification success and approval to ship product to Europe from its Carlsbad, California manufacturing facility.